Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia

References

• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics– 2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322.
   PubMed Web of Science ®Google Scholar
• Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019;18:611–621.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Banach M, Sahebkar A, et al. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother. 2019;20:791–803.
   PubMed Web of Science ®Google Scholar
• Berkhout TA, Havekes LM, Pearce NJ, et al. The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem J. 1990;272:181–186.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.
   PubMed Web of Science ®Google Scholar
• Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8:e011662.
   PubMed Web of Science ®Google Scholar
• Groot PHE, Pearce NJ, Gribble AD. ATP-citrate lyase: a potential target for hypolipidemic intervention. Curr Med Chem Immunol Endocr Metab Agents. 2003;3:211–217.
   Google Scholar
• Bilen O, Ballantyne CM. Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep. 2016 Oct;18(10):61.
   PubMed Web of Science ®Google Scholar
• Markham A. Bempedoic acid: first approval. Drugs. 2020;80:747–753.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Nilemdo (bempedoic acid): EU summary of product characteristics. 2020. Accessed 2021 Mar 28. Available from: https://ec.europa.eu/health/documents/community-register/html/h1425.htm
   Google Scholar
• Brandts J, Ray KK. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential. Expert Opin Investig Drugs. 2020;29:763–770.
   PubMed Web of Science ®Google Scholar
• Niman S, Rana K, Reid J, et al. A review of the efficacy and tolerability of bempedoic acid in the treatment of hypercholesterolemia. Am J Cardiovasc Drugs. 2020;20:535–548.
   PubMed Web of Science ®Google Scholar
• Francisco EM. Nilemdo [Internet]. European Medicines Agency. 2020 [cited 2021 Mar 13]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nilemdo.
   Google Scholar
• Esperion Therapeutics Inc. NEXLETOL (bempedoic acid): US prescribing information. 2020. Accessed 2021 Mar 28. Avaialble from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf
   Google Scholar
• Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203.
   PubMed Web of Science ®Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. CLEAR harmony trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–1032.
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322:1780–1788.
   PubMed Web of Science ®Google Scholar
• Di Minno A, Lupoli R, Calcaterra I, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9:e016262.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Fogacci F, Hernandez AV, et al. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020;17:e1003121.
   PubMed Web of Science ®Google Scholar
• Dai L, Zuo Y, You Q, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Eur J PrevCardiol. 2020;2047487320930585. DOI: https://doi.org/10.1177/2047487320930585.
   Google Scholar
• Esperion Therapeutics, Inc. A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant [internet]. clinicaltrials.gov; 2020 [cited 2021 Mar 11]. Report No.: NCT02993406. Available from: https://clinicaltrials.gov/ct2/show/NCT02993406.
   Google Scholar
• Cicero AFG, Pontremoli R, Fogacci F, et al. Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies. Drug Saf. 2020;43:727–736.
   PubMed Web of Science ®Google Scholar
• Omar M, Haas P, Ettinger M, et al. Simultaneous bilateral quadriceps tendon rupture following long-term low-dose nasal corticosteroid application. Case Rep Orthop. 2013;2013:657845.
   PubMedGoogle Scholar
• Bays HE, Banach M, Catapano AL, et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649–659.e6.
   PubMed Web of Science ®Google Scholar
• Banach M, Duell PB, Gotto AM Jr, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5(10):1124–1135.
   PubMed Web of Science ®Google Scholar
• Soslowsky LJ, Fryhofer GW. Tendon homeostasis in hypercholesterolemia. Adv Exp Med Biol. 2016;920:151–165.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Parhofer KG, Gonzalez-Juanatey JR, et al. Proportion of high-risk/very high-risk patients in europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review. Adv Ther. 2020;37:1724–1736.
   PubMed Web of Science ®Google Scholar
• Kotseva K, De Backer G, De Bacquer D, et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: a report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol. 2020;2047487320908698.
   Google Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016 Sep 27;316(12):1289–1297.
   PubMed Web of Science ®Google Scholar
• Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14:S3–28.
   PubMed Web of Science ®Google Scholar
• Pucci G, Cicero AF, Borghi C, et al. Emerging biologic therapies for hypercholesterolaemia. Expert Opin Biol Ther. 2017;17(9):1077–1087.
   PubMed Web of Science ®Google Scholar
• Gallo A, Perregaux J, Bruckert E. Advances in the management of statin myopathy. Curr Opin Endocrinol Diabetes Obes. 2021;28:142–151.
   PubMedGoogle Scholar
• Wang X, Zhang Y, Tan H, et al. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19:128.
   PubMed Web of Science ®Google Scholar
• Cheung Y-M, O’Brien R, Ekinci EI. What is new in lipid-lowering therapies in diabetes? Intern Med J. 2019;49:1472–1480.
   PubMed Web of Science ®Google Scholar